Courtney Cowell, NP
Acute Care · Wilbraham, MANPI 1134718158
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,594 of the $1,827 with a category attached, or 87.2%. It is spread thinly across 27 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $637 and has fallen 96.6% since, to $22 in 2025.
Across 74 payments — averaging $24.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$226
- Bristol Myers Squibb$209
- Pfizer$196
- Sanofi$142
- Incyte Corporation$128
- E.r. Squibb & Sons, L.L.C.$113
- plus $812 from 21 others
What the payments were for
- Food & beverage$1,59487%
- Education$23313%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 7 | $226 |
| Bristol Myers Squibb | 8 | $209 |
| Pfizer | 8 | $196 |
| Sanofi | 6 | $142 |
| Incyte Corporation | 2 | $128 |
| E.r. Squibb & Sons, L.L.C. | 5 | $113 |
| AstraZeneca | 3 | $74 |
| Eisai Inc. | 4 | $71 |
| Merck | 4 | $70 |
| Seagen Inc. | 3 | $67 |
| AVEO Pharmaceuticals, Inc. | 2 | $52 |
| Genentech USA, Inc. | 3 | $51 |
| Beigene USA, Inc. | 2 | $47 |
| Taiho Oncology, Inc. | 2 | $41 |
| Johnson & Johnson | 2 | $39 |
| Array Biopharma Inc | 2 | $39 |
| Genmab U.S., Inc. | 1 | $33 |
| Stemline Therapeutics Inc. | 1 | $31 |
| Pharmaessentia USA Corporation | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Epizyme, Inc. | 1 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| EMD Serono, Inc. | 1 | $21 |
| Dova Pharmaceuticals | 1 | $21 |
| Puma Biotechnology, Inc. | 1 | $20 |
| Servier Pharmaceuticals LLC | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
How this compares
$1,827 in reported general payments places this provider in the 85th percentile of 307 acute care providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 29 | $30,204 |
| Tamoxifen Citrate | 43 | $1,778 |
| Anastrozole | 41 | $709 |
| Hydroxyurea | 21 | $519 |
| Prochlorperazine Maleate | 21 | $480 |
| Letrozole | 13 | $288 |
| Levothyroxine Sodium | 13 | $66 |
| Prednisone | 11 | $35 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $196 | $30,20429 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 307 acute care providers in Massachusetts.
Other acute care in Wilbraham
- Bridgid JosephBoston$110K
- Pamela CalareseBoston$106K
- Kimberly GuiboneBoston$86K
- Audrey RoseWoburn$58K
- Danielle BeaulieuWest Springfield$21K
- Dawn NaylorBoston$13K
- Rebecca RathburnBoston$13K
- Morgan BowdenBoston$11K
- Javier RiveraBoston$11K
- Catherine CollierFramingham$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.